Glycopeptide phosphonate derivatives

1. A compound of formula II:

or a pharmaceutically-acceptable salt thereof;

wherein R 3 , R 5 and R 20 are selected from:

R 3

R 5

R 20

(a)

phosphono-

H

CH 3 (CH 2 ) 9 NHCH 2 CH 2 —

methylamino

(b)

phosphono-

H

CH 3 (CH 2 ) 9 OCH 2 CH 2 —

methylamino

(c)

phosphono-

H

CH 3 (CH 2 ) 9 SCH 2 CH 2 —

methylamino

(d)

phosphono-

H

CH 3 (CH 2 ) 12 —

methylamino

(e)

phosphono-

H

4-(4-chlorophenyl)benzyl

methylamino

(f)

phosphono-

H

2-(4-(4-chlorophenyl)-

methylamino

benzylamino)ethyl

(g)

phosphono-

H

4-(4′-chlorobiphenyl)butyl

methylamino

(h)

phosphono-

H

5-(4′-chlorobiphenyl)pentyl

methylamino

(i)

3-phosphono-

H

CH 3 (CH 2 ) 9 SCH 2 CH 2 —

propylamino

(j)

2-hydroxy-2-

H

4-(4-chlorophenyl)benzyl

phosphono-

ethylamino

(k)

OH

(phosphonomethyl)-

CH 3 (CH 2 ) 9 NHCH 2 CH 2 —

aminomethyl

(l)

OH

(phosphonomethyl)-

CH 3 (CH 2 ) 9 SCH 2 CH 2 —

aminomethyl

(m)

OH

(phosphonomethyl)-

CH 3 (CH 2 ) 9 OCH 2 CH 2 —

aminomethyl

(n)

OH

(phosphonomethyl)-

CH 3 (CH 2 ) 12 —

aminomethyl

(o)

OH

(phosphonomethyl)-

4-(4-chlorophenyl)benzyl

aminomethyl

(p)

OH

(phosphonomethyl)-

2-(4-(4-chlorophenyl)-

aminomethyl

benzylamino)ethyl

(q)

OH

(phosphonomethyl)-

4-(4′-chlorobiphenyl)butyl

aminomethyl

(r)

OH

(phosphonomethyl)-

5-(4′-chlorobiphenyl)pentyl

aminomethyl

(s)

OH

(phosphonomethyl)-

3-[4-(4-chlorobenzyloxy)-

aminomethyl

benzylthio]propyl

(t)

OH

N-(2-hydroxy-2-

CH 3 (CH 2 ) 9 SCH 2 CH 2 —

phosphonoethyl)-

aminomethyl

(u)

OH

N-(carboxymethyl)-

CH 3 (CH 2 ) 9 SCH 2 CH 2 —

N-2-phosphono-

methyl)aminomethyl

(v)

OH

N,N-bis(phosphono-

CH 3 (CH 2 ) 9 NHCH 2 CH 2 —

methyl)aminomethyl

(w)

OH

3-phosphonopropyl-

CH 3 (CH 2 ) 9 SCH 2 CH 2 —

aminomethyl

(x)

OH

3-phosphonopropyl-

4-(4-chlorophenyl)benzyl

aminomethyl

(y)

phosphono-

—CH 2 —N—(N—

CH 3 (CH 2 ) 9 NHCH 2 CH 2 —;

methylamino

CH 3 —D-glucamine

and

(z)

OH

(phosphonomethyl)-

—(CH 2 ) 3 NH—SO 2 —4-(4-

aminomethyl

chlorophenyl)phenyl.

2. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 1 .

3. A lyophilized composition comprising a compound of claim 1 .

4. The composition of claim 2 or 3 , wherein the composition further comprises a cyclodextrin.

5. The composition of claim 4 , wherein the cyclodextrin is hydroxypropyl-β-cyclodextrin.

6. The composition of claim 4 , wherein the cyclodextrin is sulfobutyl ether β-cyclodextrin.

7. The composition of claim 2 , wherein the composition further comprises an excipient selected from mannitol, sucrose, lactose and combinations thereof.

8. The composition of claim 2 , wherein the composition further comprises mannitol.

9. A method of treating a mammal having a bacterial disease, the method comprising administering to the mammal a therapeutically effective amount of a compound of claim 1 .

10. The method of claim 9 , wherein the bacterial disease is a staphylococcal infection.

11. The method of claim 10 , wherein the staphylococcal infection is caused by Staphylococcus aureus.

12. The method of claim 10 , wherein the staphylococcal infection is caused by Staphylococcus epidermidis.

13. The method of claim 10 , wherein the staphylococcal infection is caused by methicillin-resistant Staphylococcus aureus.

14. The method of claim 10 , wherein the staphylococcal infection is caused by methicillin-resistant Staphylococcus epidermidis.

15. The method of claim 9 , wherein the compound is administered intravenously.